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Structural Abstract. (word limit: 250) 
Aims To investigate trends in the prescription of oral anticoagulants (OAC) and antiplatelet 
agents for atrial fibrillation (AF). 
Methods Prescription data for 450,518 patients with AF from 3,352 General Practices in 
England, was obtained from the GRASP-AF registry, 2009-2018. Annualised temporal trends 
for OAC and antiplatelet prescription were reported according to eligibility based on stroke 
risk (CHADS2 or CHA2DS2-VASc scores ≥1 or >2, respectively).  
Results From 2009-2018, the prevalence of AF increased from 1.6% (95% CI 1.5-1.7%) 
to 2.4% (2.3-2.5%), and for those with AF the proportion prescribed OAC increased from 
47.6% to 75.0% (p-trend <0.001; relative risk 1.57, 95% CI 1.55-1.60) and for antiplatelet 
decreased from 37.4% to 9.2% (p-trend <0.001). In early-years (2009-2013), eligible patients 
aged ≥80 years were less likely to be prescribed OAC than patients aged <80 years (OR 0.55, 
95% CI 0.51-0.59 for CHADS2≥1 in 2009) (all p-trends <0.001). This ‘OAC prescription 
gap’ reduced over the study period (OR 0.93, 0.90-0.96 in 2018). Whilst the prescription of 
direct OAC (DOAC) as a proportion of all OAC increased from 0.1% (95% CI 0.0-0.2%) in 2011 
to 58.8% (58.4-59.2%) in 2018, it was inversely associated with patient age (p-trend<0.001) 
and their risk of stroke.  
Conclusion Between 2009-2018, in England, the use of OAC for stroke prophylaxis in AF 
increased, with DOAC accounting for over half of OAC uptake in 2018. Despite a reduction in 
the OAC-prescription gap, a new paradox exists relating to DOAC prescription for the elderly 
and those at higher risk of stroke. 





Condensed Abstract. (word limit: 50) 
This contemporary population-wide 10-year study investigated trends in prescribing oral 
anticoagulants(OAC) for atrial fibrillation (AF). The study provides good evidence for system-
wide improvements in use of OAC for stroke prophylaxis in AF. However, a paradox exists 






• This contemporary population-wide 10-year study provides good evidence for system-wide 
improvements in the use of OAC for stroke prophylaxis in AF 
• Between 2009-2018, in England, the use of OAC for stroke prophylaxis in AF increased, with 
DOAC accounting for over half of OAC uptake in 2018 
• Despite a reduction in the OAC-prescription gap, a new paradox exists relating to DOAC 





Approximately one third of ischaemic strokes are associated with atrial fibrillation (AF).(1) 
Such strokes are of importance because they are largely preventable with oral anticoagulation 
(OAC).(2) To that end, recent international guidelines for clinical practice have lowered the 
threshold for the use of OAC in stroke prophylaxis among patients with AF, and have 
emphasised their use in preference to antiplatelet (AP) drugs.(3, 4)  
With the advent of direct oral anticoagulants (DOACs), which when compared with warfarin 
reduce the frequency of cerebral haemorrhage and intracranial bleeding, there has been a 
progressive increase in the use of OAC for stroke prophylaxis in AF.(5-7) Our earlier research 
reported the temporal decline in hospitalised AF-related stroke in England (that occurred in 
the face of an increasing prevalence of AF), and postulated that this may be due to the uptake 
of OAC.(7) We have also noted a system-wide risk-treatment paradox, whereby older patients 
with AF less frequently were prescribed OAC (and more frequently offered APs).(8) This is 
resonated in the international literature,(9, 10) and of concern given the increasing 
prevalence of AF associated with an ageing population.(11, 12)  
In the UK, evidence for the underutilisation of OAC has led to national quality improvement 
initiatives to improve their uptake.(8, 13) The Guidance on Risk Assessment and Stroke 
Prevention in Atrial Fibrillation (GRASP-AF) was implemented as a national service 
improvement tool and accompanying registry in 2009 to improve OAC uptake, and in 2012 
changes to the national Quality and Outcomes Framework (QOF)(14) incentivised General 
Practitioners to use OAC in preference to APs. In addition, the National Institute for Health 
and Care Excellence (NICE) has emphasised the importance of patient choice with respect to 
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type of OAC for stroke prophylaxis in AF in patients with a CHADS2 score ≥2.(15)  Given this 
and the paucity of population-based information about the use of DOACs and, in particular, 
their use among the elderly, we used the nationwide GRASP-AF registry of 3,352 General 
Practices in England between 2009 and 2018 to study changes in OAC and AP prescription for 
stroke prophylaxis in AF.  
 
Methods 
The GRASP-AF registry 
The GRASP-AF tool, launched in 2009, was developed to help General Practitioner’s assess 
the risk of AF-related stroke and guide the effective management of patients with AF.(16) The 
tool is based on the use of Morbidity Information Query and Export SynTax (MIQUEST), a 
common query process integrated by all of the primary care computer systems in England. 
Originally the GRASP-AF tool was parameterised around the CHADS2 risk evaluation system, 
but further updated from 2011 to fit the CHA2DS2-VASc score which gives a better 
stratification of lower-risk patients. Participating General Practices voluntarily upload their 
prospective GRASP-AF data onto the central server registry. Each upload contains a snapshot 
of all eligible patients with AF and their prescription at that practice at that time. The GRASP-
AF registry was set up and is managed by PRIMIS (Primary Care Information Services) at the 
University of Nottingham. 
Patients with atrial fibrillation 
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Patients with a current, or history of AF or atrial flutter were identified through a 
comprehensive set of Read codes (Supplement table 1) from the GRASP-AF registry, 1 January 
2009 to 31 December 2018.(15, 16) For each patient, the risk of stroke was estimated from 
the components and associated coefficients of the CHADS2 score, namely each patient’s age, 
history of heart failure, hypertension, diabetes and stroke or transient ischaemic attack (see 
Read codes in Supplement table 1).(17) From 2011, the CHA2DS2-VASc score was also 
incorporated into the GRASP-AF tool by including vascular disease as well as the CHADS2 
score’s revised coefficients. (18, 19)  
 
Each General Practice recorded patient-level data using the GRASP-AF tool that included 
information about the prescription of OAC and AP therapy by CHADS2 and CHA2DS2-VASc 
scores. Data are summarised at the level of the General Practice, and uploaded onto a central 
server by participating practices. For this study, the uploaded data were aggregated by age 
bands (<30, 30-49, 50-64, 65-79 and ≥80 years), prescription of OAC or AP, and the data 
extracted separately by CHADS2 or CHA2DS2-VASc score (according to period of study). Patient 
data from the risk scores were then aggregated at four levels of stroke risk: 0, 1, 2 and >2.(7) 
Based on ESC Clinical Practice Guidelines for AF(4), OAC therapy is recommended for men 
with a stroke risk ≥1 and women with a stroke risk ≥2. Population data relating to each 
General Practice were aggregated by the same age bands. Although General Practices may 
upload data multiple times in any given year, only the first upload of the year for each practice 
was extracted for this study. 
 
Oral anticoagulation and antiplatelet therapy 
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Patients with AF within the last 6 months were identified through Read codes (Supplement 
Table 2). Their anticoagulant uptake was determined and included both vitamin K antagonists 
(warfarin, acenocoumarol and phenindione) and non-vitamin K antagonist including 
dabigatran and rivaroxaban (both first introduced in the UK in 2008), apixaban (first 
introduced in the UK in 2011) and edoxaban (first introduced in the UK in 2015). Data for AP 
prescription (aspirin, clopidogrel and dipyridamole) was similarly extracted (Supplement 
Table 2). Patients issued AP therapy were counted only if they were not co-prescribed OAC. 
 
Statistical analysis  
The prevalence of AF was calculated by year and age using the total number of patients with 
AF as a proportion of the total number of patients registered at each General Practices. The 
use of OAC and AP therapy was derived from the number of patients with AF prescribed OAC 
or AP therapy divided by the number of patients with AF across each CHADS2 or CHA2DS2-
VASc score.  
 
To determine the temporal trends of OAC and AP prescription, we used generalised linear 
models with a logit link and binomial distribution, and plotted results using cubic splines.  
Sequential models were fitted which regressed the proportion of patients with AF prescribed 
OAC or AP therapy on age band and year as well as an age by year interaction to model the 
effect of aged-related temporal changes in prescription and compared with the null model. 
Each model was weighted by the size of the General Practice. Separate models were applied 
to patients with AF stratified by their respective stroke risk score. Analyses were performed 
for patients with the CHADS2 scores across 2009-2018 and patients with the CHA2DS2-VASc 




A permutation test was performed to assess differences between the growth of the 
prescription curves of a DOAC and VKA among patients with a recorded CHA2DS2-VASc 
score.(20) The growth differences were compared according to CHA2DS2-VASc scores and age 
bands. Analyses were undertaken using R version 3.6.0 (http://www.r-project.org/). In line 
with National Health Service (NHS) research governance arrangements, ethical approval was 




Between 2009 and 2018, 3352 individual General Practices provided a total of 5968 uploads 
into the GRASP-AF database (The median number of uploads each year: 501, interquartile 
range: 407-568). From the first upload per General Practice, there were an estimated 450,518 
patients with AF from a total of 24,644,210 people, and over the study period the prevalence 
of AF was 1.8% (95% CI 1.7-1.9%), which increased from 1.6% (1.5-1.7%) in 2009 to 2.4% (2.3-
2.5%) in 2018 (p-trend <0.001, Figure 1). The prevalence of AF was stable for people aged <65 
years (p-trends not significant), but increased over time for those aged 65-79 and ≥80 years 
(p-trend, both <0.001) (Figure 1, supplement table 3).   
Temporal trends in OAC and AP prescription: CHADS2, 2009-2018 
Overall, the proportion of patients with AF who were prescribed OAC or AP was 59.4% and 
25.3%, respectively, with proportions varying across practices. Over the study period, the 
variability (interquartile range) across practices in the proportion of AF prescribed OAC and 
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AP therapy decreased from 17.6% to 10.5% and from 15.0% to 4.0% for AP therapy, 
respectively (Supplement Table 4). In the earlier years (2009-2013), the prescribing variation 
was wider by CHADS2 score, however, this variation reduced to similar level across the 
CHADS2 scores from 2015 onwards (Supplement Table 4).  
In total, 58.5% of the AF population had a CHADS2 score of ≥2 and 84.2% ≥1. There was a year-
on-year increase in the prescription of OAC with increasing CHADS2 score (Table 1). For all 
patients with AF, the proportion prescribed an OAC increased from 47.6% in 2009 to 75.0% in 
2018 (p-trend <0.001; relative risk 1.57, 95% CI 1.55-1.60), whereas the proportion prescribed 
an AP decreased from 37.4% to 9.2% over the same period (p-trend <0.001). Moreover, a 
pattern of an increase in OAC and decrease in AP prescription was evident across each of the 
CHADS2 scores (Table 1). 
Although OAC prescription increased over time, in the earlier years (2009-2013) patients aged 
≥80 years were less likely to be prescribed OAC than patients aged <80 years, for all CHADS2 
scores ≥1 (Figure 2). However, results from general linear models stratified by CHADS2 score 
found that, each year, the ‘OAC prescription gap’ between patients aged ≥80 and <80 years 
reduced annually by 1.2% (95% CI: 0.2-2.2%) for CHADS2 = 1, 1.6% (95% CI: 0.9-2.3%) for 
CHADS2 = 2, and 1.8% (95% CI: 1.3-2.4%) for CHADS2 >2. In parallel, the ‘AP prescription gap’ 
for the same age bands reduced by a similar magnitude (Figure 2). At the end of the study in 
2018, there was an OAC-prescription gap between age ≥80 years and age <80 years for 
CHADS2 >2 (OR 0.63, 95% CI:0.58-0.67) and CHADS2 = 2 (OR 0.79, 95% CI: 0.74-0.84), but not 
for CHADS2 = 1 (OR: 0.95, 95% CI: 0.89-1.02). 
Temporal trends in OAC and AP prescription: CHA2DS2-VASc, 2011-2018 
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Overall, 62.5% of patients with AF were prescribed OAC (45.8% VKA and 16.5% DOAC), and 
21.9% of patients with AF were prescribed AP therapy (Table 2 and Supplement Table 5).  
In total, 84.7% of the AF population had a CHA2DS2-VASc score ≥2 and 94.5% ≥1. There was a 
year-on-year increase in the prescription of OACs with increasing CHA2DS2-VASc score (Table 
2). For all patients with AF, the proportion prescribed OAC increased from 49.6% in 2011 to 
75.0% in 2018 (p-trend <0.001, Table 2), whereas the proportion prescribed an AP decreased 
from 34.6% to 9.2% over the same period (p-trend <0.001, Supplement Table 5). Even so, at 
the end of 2018 less than 10% of General Practices achieved levels of 80% OAC prescription 
for eligible patients with a CHA2DS2-VASc score ≥2 and age ≥80 years.   
Although OAC prescription did increase over time, for the earlier years (2009-2013) patients 
aged ≥80 years were less likely to be prescribed OAC than patients aged <80 years, for all 
CHA2DS2-VASc scores >2 (Figure 3). Nonetheless, analyses stratified by CHA2DS2-VASc score 
found that, each year, the ‘OAC prescription gap’ between patients aged ≥80 and <80 years 
reduced annually by 1.7% (95% CI: 1.2-2.3%) for CHA2DS2-VASc score >2, with a corresponding 
reduction in the magnitude of the ‘AP prescription gap’ for the same age bands (Figure 3). At 
the end of the study in 2018, there was an OAC-prescription gap between age ≥80 years and 
age <80 years for CHA2DS2-VASc >2 (OR 0.74, 95% CI: 0.71-0.77), but not for CHA2DS2-VASc = 
2 (OR 0.90, 95% CI: 0.81-1.00). 
Prescription of DOACs 
Overall, 26.4% of patients prescribed OAC received a DOAC. DOAC prescription increased 
from 0.1% in 2011 to 58.8% of all OAC in 2018 (p-trend <0.001, Table 2), while VKA 
prescription decreased from 99.6% to 41.1% over the same period (p-trend <0.001, Table 2). 
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The prescription of DOACs increased at a faster rate among patients with a lower CHA2DS2-
VASc score (pairwise comparisons after adjustment for multiple comparison, all p-values 
<0.001 Figure 4). Furthermore, for patients with the same CHA2DS2-VASc score, patients aged 
<65 years were more likely to be prescribed a DOAC than patients in older age bands (all p-
values < 0.01 after adjustment for multiple comparison, Figure 5). At the end of the study in 
2018, there was a DOAC-prescription gap between age <65 and 65-79 years for CHA2DS2-VASc 
score =1 (OR 0.79, 95% CI: 0.72-0.87); a DOAC-prescription gap for CHA2DS2-VASc score ≥ 2 
(OR 0.74, 95% CI: 0.69-0.80 for age 65-79 years; OR 0.70, 95% CI: 0.65-0.75 for age ≥80 years) 
compared with prescription for patients age <65 years.  
 
Discussion 
This population-based, multicenter, 10-year study of the use of OAC for stroke prophylaxis for 
patients with AF found that the prescription of OAC for patients with AF at high risk of stroke 
increased by nearly 60%.  By 2018 about three quarters of all patients recorded in primary 
care in England with AF and a CHADS2 or CHA2DS2-VASc score ≥2 were receiving OAC. This 
increase in OAC prescription occurred at a time of a dramatic rise in the prescription of DOACs. 
Beyond the decline in the use of AP therapy, however, there was evidence for General 
Practice level variation in the use of OAC for stroke prophylaxis, which although decreased 
over the study period was still evident in 2018 and suggests that the potential to reduce the 
risk of AF-related stroke has not been fully realized.  In addition, there was a clear ‘OAC 
prescription gap’ among the elderly, which was evident for the prescription of DOAC.  
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Overall, the prescription of OAC for patients with AF increased by nearly 30% over 10 years; 
in the UK before 2011 less than 50% of patients with AF were prescribed OAC. The use of OAC 
for stroke prophylaxis in AF increased from circa the publication of the 2010 ESC Clinical 
Practice Guidelines for the management of AF, which recommended the use of OAC for all 
patients at moderate to high risk of stroke (CHA2DS2-VASc score ≥1)(11), and a 2012 
recommendation that the prescription of AP drugs was no longer suitable for stroke 
prophylaxis in low-risk patients with AF, unless patients refused or were ineligible for any type 
of OAC.(21) Yet, other factors may have contributed to the change in prescribing habits 
including quality improvement initiatives such as deployment of the nationwide GRASP-AF 
tool, heightened physician awareness and familiarity with the CHADS2 and CHA2DS2-VASc 
scores, and the availability from 2011 of alternatives to VKA in the form of DOACs.  
Specifically, we found that the age-dependent ‘OAC prescription gap’ reduced by nearly 20% 
- a reduction which was consistent across the moderate to high risk of stroke patients 
(determined either by CHADS2 or CHA2DS2-VASc score), and by the end of the study in 2018 
OAC prescribing was less age-dependent. However, there remained inequalities in the 
delivery of care, evidenced by variation in the use of OAC across General Practices.(22-24) 
Such variation suggests that the opportunity to improve the uptake of OAC for stroke 
prophylaxis among patients with AF has not been accomplished. By contrast, we found that 
the prescription of OAC among patients with a CHA2DS2-VASc of 0 increased over the study 
period, suggesting that in addition to the underuse of OAC among higher risk patients, there 
is evidence for overuse of OAC for stroke prophylaxis in AF for those in whom it may not be 
appropriate. We can only speculate as to why this may be the case, and that it relates to a 
misperception of the balance of benefit and harm in this low risk group. That is, patients with 
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AF who are at low risk of stroke may be inappropriately prescribed OAC because they are felt 
to be at low risk of bleeding events associated with OAC and the risk of stroke if they do not 
receive OAC when in fact their relative gain from stroke prophylaxes is negligible.   
We found that the prescription of DOACs increased substantially over the 10 years of study, 
to account for nearly 60% of all OAC prescription at the end of 2018. DOACs have been shown 
to be superior to VKA in stroke prevention, and carry similar overall bleeding risk.(25-28) 
Despite this, we found that for all higher stroke risk categories, the uptake of DOACs was 
inversely associated with age and estimated risk of stroke, and at the end of the study there 
was a reduced, but persisting ‘DOAC prescription gap’. That is, there is good evidence to 
support the notion of an on-going risk-treatment paradox for the use of DOACs in the elderly, 
with higher stroke risk patients over the age of 80 years less frequently prescribed DOACs 
than VKA overall. It is plausible that for DOACs their remains risk-adverse strategy among 
healthcare professionals, again because of the misperception that OAC is associated with 




For this study, the GRASP-AF registry included 3352 individual General Practices, which 
represents about half of all General Practices in England. Despite this large sample size, data 
are uploaded voluntarily at each General Practice, and therefore may not be fully 
representative of the population as a whole.(16) The proportion of patients aged ≥65 years in 
the analytical cohort, is slightly higher than that reported by the Office for National Statistics 
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estimate for England (17.4% vs 16.5%), again highlighting potential limitations in 
generalisability. The prevalence of AF was calculated according to the diagnostic code in the 
GRASP-AF tool, and in doing so may incur an improper estimation. Furthermore, some 
information such as sex and history of bleeding or other contra-indications to OAC is not 
separately available in the GRASP-AF data extraction, which prevents any inference about the 
justification for prescribing patterns. This registry data did not specify whether the 
prescription was for patients with newly diagnosed AF, we were unable to investigate 
whether the reducing prescription gap was due to therapy switching, but recognize that there 
is likely to be a legacy effect of chronic VKA prescription and that this might affect age bands 
differently. We acknowledge the limitations of the ecological study design, and given the 
observational nature of the study that causation is not implied.  
 
Conclusion  
This contemporary population-wide 10-year study provides good evidence for system-wide 
improvements in the use of OAC for stroke prophylaxis in AF. The pronounced uptake in the 
use of DOACs in this population is likely to have been a driver in improvement in overall OAC 
uptake and to have contributed, moreover, to a marked reduction in the historical age-related 
OAC risk-treatment paradox. Nonetheless, this study suggests that a new paradox, relating to 
DOAC for the elderly and higher stroke risk, exists. Local and national strategies are now 
required to eliminate such inequity in care so that reductions in potentially preventable AF-
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